Last updated on March 2018

Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer


Brief description of study

The primary purpose of this phase 1 study is to determine the dose-dependent toxicity and maximum tolerated dose (MTD) of oncolytic adenovirus-mediated cytotoxic and IL-12 gene therapy in men with locally recurrent prostate cancer after definitive radiotherapy

Clinical Study Identifier: NCT02555397

Find a site near you

Start Over

Henry Ford Health System

Detroit, MI United States
  Connect »